Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Shengli Xia; Yuntao Zhang; Yanxia Wang; Hui Wang; Yunkai Yang; George F. Gao; Wenjie Tan; Guizhen Wu; Miao Xu; Zhiyong Lou; Weijin Huang; Wenbo Xu; Baoying Huang; Wei Wang; Wei Zhang; Na Li; Zhiqiang Xie; Xiujuan Zhu; Ling Ding; Wangyang You; Yuxiu Zhao; Jun Zhao; Lili Huang; Xuezhong Shi; Yongli Yang; Guangxue Xu; WenLing Wang; Peipei Liu; Meng Ma; YuLing Qiao; Suhua Zhao; Jingjing Chai; QinQin Li; Hui Fu; Ying Xu; Xiaotong Zheng; Wanshen Guo; Xiaoming Yang

doi:10.1016/s1473-3099(21)00462-x

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial

Shengli Xia(Henan Provincial Center for Disease Control and Prevention), Yuntao Zhang(National Vaccine and Serum Institute), Yanxia Wang(Henan Provincial Center for Disease Control and Prevention), Hui Wang(National Vaccine and Serum Institute), Yunkai Yang(Zhengzhou University), George F. Gao(Chinese Center For Disease Control and Prevention), Wenjie Tan(Chinese Center For Disease Control and Prevention), Guizhen Wu(Chinese Center For Disease Control and Prevention), Miao Xu(National Institutes for Food and Drug Control), Zhiyong Lou(Tsinghua University), Weijin Huang(National Institutes for Food and Drug Control), Wenbo Xu(Chinese Center For Disease Control and Prevention), Baoying Huang(Chinese Center For Disease Control and Prevention), Wei Wang(Chinese Center For Disease Control and Prevention), Wei Zhang(Henan Provincial Center for Disease Control and Prevention), Na Li(National Vaccine and Serum Institute), Zhiqiang Xie(Henan Provincial Center for Disease Control and Prevention), Xiujuan Zhu(National Vaccine and Serum Institute), Ling Ding(National Vaccine and Serum Institute), Wangyang You(Henan Provincial Center for Disease Control and Prevention), Yuxiu Zhao(National Vaccine and Serum Institute), Jun Zhao(National Vaccine and Serum Institute), Lili Huang(Henan Provincial Center for Disease Control and Prevention), Xuezhong Shi(Zhengzhou University), Yongli Yang(Zhengzhou University), Guangxue Xu(Tsinghua University), WenLing Wang(Chinese Center For Disease Control and Prevention), Peipei Liu(Chinese Center For Disease Control and Prevention), Meng Ma(National Vaccine and Serum Institute), YuLing Qiao(National Vaccine and Serum Institute), Suhua Zhao(National Vaccine and Serum Institute), Jingjing Chai(National Vaccine and Serum Institute), QinQin Li(National Vaccine and Serum Institute), Hui Fu(National Vaccine and Serum Institute), Ying Xu(National Vaccine and Serum Institute), Xiaotong Zheng(National Vaccine and Serum Institute), Wanshen Guo(Henan Provincial Center for Disease Control and Prevention), Xiaoming Yang(China National Pharmaceutical Group Corporation (China))

The Lancet Infectious Diseases

September 15, 2021

10.1016/s1473-3099(21)00462-x

Cited by 201Open Access

Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis